Neutral
How Investors May Respond To Rapport Therapeutics (RAPP) Phase 2a RAP-219 Data Spotlight At AAN 2026
Rapport Therapeutics (RAPP) will present new 8-week follow-up data from its Phase 2a trial of RAP-219 for focal onset seizures at the 2026 American Ac...